| Year |
Citation |
Score |
| 2019 |
Shang S, Yang J, Jazaeri AA, Duval AJ, Tufan T, Lopes Fischer N, Benamar M, Guessous F, Lee I, Campbell RM, Ebert PJ, Abbas T, Landen CN, DiFeo A, Scacheri PC, et al. Chemotherapy-induced distal enhancers drive transcriptional program to maintain the chemoresistant state in ovarian cancer. Cancer Research. PMID 31358529 DOI: 10.1158/0008-5472.Can-19-0215 |
0.416 |
|
| 2018 |
Collins G, Mesiano S, DiFeo A. Effects of Metformin on Cellular Proliferation and Steroid Hormone Receptors in Patient-Derived, Low-Grade Endometrial Cancer Cell Lines. Reproductive Sciences (Thousand Oaks, Calif.). 1933719118779734. PMID 29848180 DOI: 10.1177/1933719118779734 |
0.353 |
|
| 2018 |
Belur Nagaraj A, Kovalenko O, Avelar RA, Joseph P, Brown A, Surti A, Mantilla S, DiFeo A. Mitotic Exit dysfunction through the deregulation of APC/C characterizes cisplatin resistant state in epithelial ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29653924 DOI: 10.1158/1078-0432.Ccr-17-2885 |
0.374 |
|
| 2018 |
McClinch K, A Avelar R, Callejas D, Izadmehr S, Wiredja D, Perl A, Sangodkar J, Kastrinsky DB, Schlatzer D, Cooper M, Kiselar J, Stachnik A, Yao S, Hoon D, McQuaid D, ... ... DiFeo A, et al. Small molecule activators of protein phosphatase 2A for the treatment of castration-resistant prostate cancer. Cancer Research. PMID 29358171 DOI: 10.1158/0008-5472.Can-17-0123 |
0.381 |
|
| 2018 |
Morrow JJ, Bayles I, Funnell APW, Miller TE, Saiakhova A, Lizardo MM, Bartels CF, Kapteijn MY, Hung S, Mendoza A, Dhillon G, Chee DR, Myers JT, Allen F, Gambarotti M, ... ... DiFeo A, et al. Positively selected enhancer elements endow osteosarcoma cells with metastatic competence. Nature Medicine. PMID 29334376 DOI: 10.1038/Nm.4475 |
0.396 |
|
| 2018 |
Nagaraj AB, Joseph P, Knarr M, Kovalenko O, Surti A, DiFeo A. Abstract B66: miRNA 3’UTR activity driven enrichment of ovarian tumor-initiating cells (TICs) to overcome the barriers of heterogeneity and TIC plasticity Clinical Cancer Research. 24. DOI: 10.1158/1557-3265.Ovca17-B66 |
0.35 |
|
| 2018 |
Hopp E, Joseph P, Nakayama J, Zanotti K, Nagel C, Waggoner S, DiFeo A. Identifying susceptibilities and pharmacodynamic biomarkers for mirvetuximab soravtansine in high-grade ovarian and endometrial cancer Gynecologic Oncology. 149: 57. DOI: 10.1016/J.Ygyno.2018.04.126 |
0.37 |
|
| 2018 |
Collins G, Zolton J, Mesiano S, Difeo A. The effects of metformin on cellular proliferation and steroid hormone receptor expression in patient derived low grade endometrial cancer cell lines: implications for reproductive sparing treatment using metformin Fertility and Sterility. 109: e21. DOI: 10.1016/J.Fertnstert.2018.02.045 |
0.359 |
|
| 2017 |
Nagaraj AB, Wang QQ, Joseph P, Zheng C, Chen Y, Kovalenko O, Singh S, Armstrong A, Resnick K, Zanotti K, Waggoner S, Xu R, DiFeo A. Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment. Oncogene. PMID 28967908 DOI: 10.1038/Onc.2017.328 |
0.34 |
|
| 2017 |
Saygin C, Wiechert A, Rao VS, Alluri R, Connor E, Thiagarajan PS, Hale JS, Li Y, Chumakova A, Jarrar A, Parker Y, Lindner DJ, Nagaraj AB, Kim JJ, DiFeo A, et al. CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors. The Journal of Experimental Medicine. PMID 28838952 DOI: 10.1084/Jem.20170438 |
0.324 |
|
| 2017 |
Sangodkar J, Perl A, Tohme R, Kiselar J, Kastrinsky DB, Zaware N, Izadmehr S, Mazhar S, Wiredja DD, O'Connor CM, Hoon D, Dhawan NS, Schlatzer D, Yao S, Leonard D, ... ... DiFeo A, et al. Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth. The Journal of Clinical Investigation. PMID 28504649 DOI: 10.1172/Jci89548 |
0.433 |
|
| 2017 |
Singh S, Swarer K, DiFeo A, Sawady J, Syriac S, Resnick KE. Prognostic influence of BRCA 1 somatic mutations in African Amercian versus Caucasian ovarian cancer patients. Journal of Clinical Oncology. 35: e17054-e17054. DOI: 10.1200/Jco.2017.35.15_Suppl.E17054 |
0.357 |
|
| 2017 |
Nagaraj AB, Wang Q, Kovalenko O, Joseph P, Chen Y, Xu R, DiFeo A. Abstract NTOC-081: PHARMACOLOGIC ANALYSIS OF HIGH–GRADE SEROUS OVARIAN CANCER TCGA DATASET IDENTIFIES A NOVEL CHEMO–ADJUVANT ROLE FOR NON–STEROIDAL ANTI–INFLAMMATORY DRUGS (NSAIDS) Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Ovcasymp16-Ntoc-081 |
0.383 |
|
| 2017 |
Connor R, Nagaraj A, Joseph P, Mantilla S, Kovalenko O, Nagel C, Nakayama J, Waggoner S, Zanotti K, Singh S, DiFeo A. The wnt/β-catenin-specific inhibitor, ICG-001, proves effective for the treatment of high-grade serous ovarian cancer in murine models through the targeting of cancer initiating cells Gynecologic Oncology. 145: 120-121. DOI: 10.1016/J.Ygyno.2017.03.283 |
0.385 |
|
| 2017 |
Armstrong A, Joseph P, Nagaraj A, Nagel C, Nakayama J, Waggoner S, Zanotti K, DiFeo A, Narla G. The use of novel PP2A activators in combination withPARP inhibitor for the treatment of high-grade serous ovarian cancer Gynecologic Oncology. 145: 73. DOI: 10.1016/J.Ygyno.2017.03.173 |
0.357 |
|
| 2016 |
Dimitrova N, Nagaraj AB, Razi A, Singh S, Kamalakaran S, Banerjee N, Joseph P, Mankovich A, Mittal P, DiFeo A, Varadan V. InFlo: a novel systems biology framework identifies cAMP-CREB1 axis as a key modulator of platinum resistance in ovarian cancer. Oncogene. PMID 27819677 DOI: 10.1038/Onc.2016.398 |
0.373 |
|
| 2016 |
Hudson CD, Savadelis A, Nagaraj AB, Joseph P, Avril S, DiFeo A, Avril N. Altered glutamine metabolism in platinum resistant ovarian cancer. Oncotarget. PMID 27191653 DOI: 10.18632/Oncotarget.9317 |
0.36 |
|
| 2016 |
Wiechert A, Saygin C, Thiagarajan PS, Rao VS, Hale JS, Gupta N, Hitomi M, Nagaraj AB, DiFeo A, Lathia JD, Reizes O. Cisplatin induces stemness in ovarian cancer. Oncotarget. PMID 27105520 DOI: 10.18632/Oncotarget.8852 |
0.402 |
|
| 2016 |
Petrillo M, Zannoni GF, Beltrame L, Martinelli E, DiFeo A, Paracchini L, Craparotta I, Mannarino L, Vizzielli G, Scambia G, D'Incalci M, Romualdi C, Marchini S. Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 27: 625-34. PMID 26782955 DOI: 10.1093/Annonc/Mdw007 |
0.329 |
|
| 2016 |
Saygin C, Wiechert A, Thiagarajan P, Rao V, Hale J, Hitomi M, DiFeo A, Lathia J, Reizes O. Cisplatin to induce cancer stem cell state in ovarian cancer. Journal of Clinical Oncology. 34: e17098-e17098. DOI: 10.1200/Jco.2016.34.15_Suppl.E17098 |
0.383 |
|
| 2016 |
Singh S, DiFeo A, Shojaei H, Redline R, Resnick KE. The prognostic significance of cancerous inhibitor of PP2A (CIP2A) expression in cervical cancer (CC). Journal of Clinical Oncology. 34: e17019-e17019. DOI: 10.1200/Jco.2016.34.15_Suppl.E17019 |
0.408 |
|
| 2016 |
Morrow JJ, Miller TE, Saiakhova A, Lizardo MM, Bartels CF, Bayles I, Hung S, Mendoza A, Myers JT, Allen F, DiFeo A, Rubin BP, Huang AY, Meltzer PS, Helman LJ, et al. Abstract LB-151: Positively selected enhancer elements endow tumor cells with metastatic competence Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-151 |
0.419 |
|
| 2016 |
Farrington CC, Wang X, Janghorban M, Liang J, Difeo A, Sears R, Narla G. Abstract 3857: Pharmacological reactivation of the tumor suppressor protein phosphatase 2A as a novel approach for the treatment of breast cancer Cancer Research. 76: 3857-3857. DOI: 10.1158/1538-7445.Am2016-3857 |
0.406 |
|
| 2016 |
Wiechert A, Saygin C, Thiagarajan P, Hale J, Michener C, DiFeo A, Lathia J, Reizes O. Development and validation of a fluorescent reporter system for ovarian cancer stem cells Gynecologic Oncology. 141: 163. DOI: 10.1016/J.Ygyno.2016.04.424 |
0.333 |
|
| 2015 |
Wang Y, Deng O, Feng Z, Du Z, Xiong X, Lai J, Yang X, Xu M, Wang H, Taylor D, Yan C, Chen C, Difeo A, Ma Z, Zhang J. RNF126 promotes homologous recombination via regulation of E2F1-mediated BRCA1 expression. Oncogene. PMID 26234677 DOI: 10.1038/Onc.2015.198 |
0.43 |
|
| 2015 |
Nagaraj AB, Joseph P, Kovalenko O, Singh S, Armstrong A, Redline R, Resnick K, Zanotti K, Waggoner S, DiFeo A. Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance. Oncotarget. PMID 26125441 DOI: 10.18632/Oncotarget.4690 |
0.362 |
|
| 2015 |
Nagaraj AB, Joseph P, DiFeo A. miRNAs as prognostic and therapeutic tools in epithelial ovarian cancer. Biomarkers in Medicine. 9: 241-57. PMID 25731210 DOI: 10.2217/Bmm.14.108 |
0.313 |
|
| 2015 |
Singh S, DiFeo A, Redline R, Shojaei H, Resnick KE. Association of Protein Phosphatase 2A (PP2A) overexpression with improved survival in patients with locally-advanced cervical cancer. Journal of Clinical Oncology. 33: e16594-e16594. DOI: 10.1200/Jco.2015.33.15_Suppl.E16594 |
0.419 |
|
| 2015 |
Singh S, Joseph P, Nagaraj A, Armstrong A, Resnick K, Zanotti K, Waggoner S, Narla G, DiFeo A. Small molecule activators of protein phosphatase 2A for the treatment of endometrial cancer Gynecologic Oncology. 137: 208. DOI: 10.1016/J.Ygyno.2015.01.523 |
0.346 |
|
| 2014 |
Sivendran S, Chang R, Pham L, Phelps RG, Harcharik ST, Hall LD, Bernardo SG, Moskalenko MM, Sivendran M, Fu Y, de Moll EH, Pan M, Moon JY, Arora S, Cohain A, ... DiFeo A, et al. Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II-III resectable disease. The Journal of Investigative Dermatology. 134: 2202-11. PMID 24522433 DOI: 10.1038/Jid.2014.85 |
0.33 |
|
| 2014 |
Carter RR, DiFeo A, Bogie K, Zhang GQ, Sun J. Crowdsourcing awareness: exploration of the ovarian cancer knowledge gap through Amazon Mechanical Turk. Plos One. 9: e85508. PMID 24465580 DOI: 10.1371/Journal.Pone.0085508 |
0.377 |
|
| 2014 |
Parikh A, Lee C, Joseph P, Marchini S, Baccarini A, Kolev V, Romualdi C, Fruscio R, Shah H, Wang F, Mullokandov G, Fishman D, D'Incalci M, Rahaman J, Kalir T, ... ... DiFeo A, et al. microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition. Nature Communications. 5: 2977. PMID 24394555 DOI: 10.1038/Ncomms3977 |
0.351 |
|
| 2014 |
Sangodkar J, Mazhar S, Wiredja D, Gokulrangan G, Schlatzer D, Kastrinsky D, Difeo A, Yao S, Izadmehr S, Sharma N, Ioannou Y, Ohlmeyer M, Narla G. Abstract A38: Therapeutic targeting of oncogenic KRAS signaling using a novel small molecule agonist of the PP2A tumor suppressor gene Molecular Cancer Research. 12. DOI: 10.1158/1557-3125.Rasonc14-A38 |
0.421 |
|
| 2013 |
Mosoyan G, Nagi C, Marukian S, Teixeira A, Simonian A, Resnick-Silverman L, DiFeo A, Johnston D, Reynolds SR, Roses DF, Mosoian A. Multiple breast cancer cell-lines derived from a single tumor differ in their molecular characteristics and tumorigenic potential. Plos One. 8: e55145. PMID 23372829 DOI: 10.1371/Journal.Pone.0055145 |
0.366 |
|
| 2013 |
Hatami R, Sieuwerts AM, Izadmehr S, Yao Z, Qiao RF, Papa L, Look MP, Smid M, Ohlssen J, Levine AC, Germain D, Burstein D, Kirschenbaum A, DiFeo A, Foekens JA, et al. KLF6-SV1 drives breast cancer metastasis and is associated with poor survival. Science Translational Medicine. 5: 169ra12. PMID 23345610 DOI: 10.1126/Scitranslmed.3004688 |
0.407 |
|
| 2013 |
Favier R, DiFeo A, Hezard N, Fabre M, Bedossa P, Martignetti JA. A new feature of the MYH9-related syndrome: chronic transaminase elevation. Hepatology (Baltimore, Md.). 57: 1288-9. PMID 22806255 DOI: 10.1002/Hep.25913 |
0.516 |
|
| 2013 |
Sivendran S, Chang RR, Harcharik S, Hall L, Bernardo S, Moskalenko M, Phelps R, Sivendran M, Cohain A, DiFeo A, Parides M, Lebwohl M, Friedlander P, Banchereau J, Bhardwaj N, et al. Immune gene expression in primary melanomas to predict lower risk of recurrence and death. Journal of Clinical Oncology. 31: 3014-3014. DOI: 10.1200/Jco.2013.31.15_Suppl.3014 |
0.304 |
|
| 2013 |
Parikh A, Lee C, Joseph P, Marchini S, Baccarini A, Kolev V, Romualdi C, Fruscio R, Shah H, Feng W, Mullokandov G, Fishman D, D'Incalci M, Rahaman J, Kalir T, ... ... DiFeo A, et al. Abstract B47: microRNA-181a plays a critical role in ovarian cancer progression through the regulation of epithelial-mesenchymal transition Clinical Cancer Research. 19: 47-47. DOI: 10.1158/1078-0432.Ovca13-B47 |
0.41 |
|
| 2012 |
Sangodkar J, Dhawan NS, Melville H, Singh VJ, Yuan E, Rana H, Izadmehr S, Farrington C, Mazhar S, Katz S, Albano T, Arnovitz P, Okrent R, Ohlmeyer M, Galsky M, ... ... Difeo A, et al. Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response. The Journal of Clinical Investigation. 122: 2637-51. PMID 22653055 DOI: 10.1172/Jci62058 |
0.327 |
|
| 2012 |
Calderon MR, Verway M, An BS, DiFeo A, Bismar TA, Ann DK, Martignetti JA, Shalom-Barak T, White JH. Ligand-dependent corepressor (LCoR) recruitment by Kruppel-like factor 6 (KLF6) regulates expression of the cyclin-dependent kinase inhibitor CDKN1A gene. The Journal of Biological Chemistry. 287: 8662-74. PMID 22277651 DOI: 10.1074/Jbc.M111.311605 |
0.627 |
|
| 2012 |
Izadmehr S, Lee CH, Fernandez H, Hatami R, Kirschenbaum A, Levine AC, Difeo A, Narla G. Abstract A57: Functional synergy between the KLF6-SV1 and c-MYC oncogenes in driving prostate cancer metastasis in a novel mouse model of the disease Cancer Research. 72: A57-A57. DOI: 10.1158/1538-7445.Prca2012-A57 |
0.418 |
|
| 2012 |
Hatami R, Ohlseen J, Izadmehr S, Sieuwerts AM, Papa L, Kirschenbaum A, Levine A, Germain D, Foekens JA, DiFeo A, Narla G. Abstract 5314: An oncogenic splice variant of the KLF6 tumor suppressor gene is associated with poor survival and is a potent driver of breast cancer metastasis Cancer Research. 72: 5314-5314. DOI: 10.1158/1538-7445.Am2012-5314 |
0.437 |
|
| 2012 |
Sangodkar J, Dhawan N, Melville H, Singh VJ, Farrington C, Yuan E, Rana H, Smith B, Gidwani V, Okrent R, Burstein D, Ohlmeyer M, Politi K, DiFeo A, Narla G. Abstract 1885: Targeting the FOXO1/KLF6 transcriptional network to modulate response to anti-EGFR based therapy Cancer Research. 72: 1885-1885. DOI: 10.1158/1538-7445.Am2012-1885 |
0.379 |
|
| 2011 |
Sanborn KB, Mace EM, Rak GD, Difeo A, Martignetti JA, Pecci A, Bussel JB, Favier R, Orange JS. Phosphorylation of the myosin IIA tailpiece regulates single myosin IIA molecule association with lytic granules to promote NK-cell cytotoxicity. Blood. 118: 5862-71. PMID 22123909 DOI: 10.1182/Blood-2011-03-344846 |
0.559 |
|
| 2011 |
Poopak B, Rezvani H, Difeo A, Martignetti JA, Khosravipour G, Yousefian A, Farahani K, Haghnejad Doshanlo F, Saki N. The first report of homozygous May-Hegglin anomaly E1841K mutation. European Journal of Haematology. 86: 357. PMID 21083612 DOI: 10.1111/J.1600-0609.2010.01553.X |
0.555 |
|
| 2011 |
Radbill BD, Gupta R, Ramirez MC, DiFeo A, Martignetti JA, Alvarez CE, Friedman SL, Narla G, Vrabie R, Bowles R, Saiman Y, Bansal MB. Loss of matrix metalloproteinase-2 amplifies murine toxin-induced liver fibrosis by upregulating collagen I expression. Digestive Diseases and Sciences. 56: 406-16. PMID 20563750 DOI: 10.1007/S10620-010-1296-0 |
0.548 |
|
| 2011 |
Sangodkar J, Katz S, Melville H, Singh V, Dhawan N, DiFeo A, Narla G. Abstract 2899: Restoring sensitivity to anti-EGFR-based therapy in lung adenocarcinoma by downstream modulation of the FOXO1/KLF6 transcriptional network Cancer Research. 71: 2899-2899. DOI: 10.1158/1538-7445.Am2011-2899 |
0.391 |
|
| 2011 |
Bradley W, Dottino P, Rahaman J, DiFeo A, Martignetti J. The tumor suppressor KLF6, lost in a majority of ovarian cancer cases, represses VEGF expression levels Gynecologic Oncology. 120: S57. DOI: 10.1016/J.Ygyno.2010.12.137 |
0.634 |
|
| 2011 |
Fishman D, Wang F, DiFeo A, Narla G. Quantitative PCR array identification of microRNA clusters associated with epithelial ovarian cancer chemoresistance Gynecologic Oncology. 120: S54. DOI: 10.1016/J.Ygyno.2010.12.131 |
0.332 |
|
| 2011 |
DiFeo A, Sennet R, Huang F, Levine D, Kalir T, van de Rijn M, Dottino P, Martignetti J. KLF6-SV1 is a novel uterine leiomyosarcoma gene: From transgenic mouse model to human disease Gynecologic Oncology. 120: S8. DOI: 10.1016/J.Ygyno.2010.12.022 |
0.565 |
|
| 2010 |
Rodríguez E, Aburjania N, Priedigkeit NM, DiFeo A, Martignetti JA. Nucleo-cytoplasmic localization domains regulate Krüppel-like factor 6 (KLF6) protein stability and tumor suppressor function. Plos One. 5. PMID 20844588 DOI: 10.1371/Journal.Pone.0012639 |
0.626 |
|
| 2010 |
Sangodkar J, Katz S, Albano T, Melville H, Burstein D, Politi K, Difeo A, Narla G. Abstract B41: Restoring sensitivity to anti-EGFR-based therapy in lung adenocarcinoma by downstream modulation of the FOXO1/KLF6 transcriptional network Clinical Cancer Research. 16. DOI: 10.1158/1078-0432.Tcmusa10-B41 |
0.359 |
|
| 2009 |
DiFeo A, Narla G, Martignetti JA. Emerging roles of Kruppel-like factor 6 and Kruppel-like factor 6 splice variant 1 in ovarian cancer progression and treatment. The Mount Sinai Journal of Medicine, New York. 76: 557-66. PMID 20014424 DOI: 10.1002/Msj.20150 |
0.671 |
|
| 2009 |
Sanborn KB, Rak GD, Maru SY, Demers K, Difeo A, Martignetti JA, Betts MR, Favier R, Banerjee PP, Orange JS. Myosin IIA associates with NK cell lytic granules to enable their interaction with F-actin and function at the immunological synapse. Journal of Immunology (Baltimore, Md. : 1950). 182: 6969-84. PMID 19454694 DOI: 10.4049/Jimmunol.0804337 |
0.558 |
|
| 2009 |
Difeo A, Huang F, Sangodkar J, Terzo EA, Leake D, Narla G, Martignetti JA. KLF6-SV1 is a novel antiapoptotic protein that targets the BH3-only protein NOXA for degradation and whose inhibition extends survival in an ovarian cancer model. Cancer Research. 69: 4733-41. PMID 19435908 DOI: 10.1158/0008-5472.Can-08-4282 |
0.644 |
|
| 2009 |
Xiong SD, Yu K, Liu XH, Yin LH, Kirschenbaum A, Yao S, Narla G, DiFeo A, Wu JB, Yuan Y, Ho SM, Lam YW, Levine AC. Ribosome-inactivating proteins isolated from dietary bitter melon induce apoptosis and inhibit histone deacetylase-1 selectively in premalignant and malignant prostate cancer cells. International Journal of Cancer. 125: 774-82. PMID 19384952 DOI: 10.1002/Ijc.24325 |
0.363 |
|
| 2009 |
Sangodkar J, DiFeo A, Feld L, Bromberg R, Schwartz R, Huang F, Terzo EA, Choudhri A, Narla G. Targeted reduction of KLF6-SV1 restores chemotherapy sensitivity in resistant lung adenocarcinoma. Lung Cancer (Amsterdam, Netherlands). 66: 292-7. PMID 19328586 DOI: 10.1016/J.Lungcan.2009.02.014 |
0.416 |
|
| 2009 |
Deuquet J, Abrami L, Difeo A, Ramirez MC, Martignetti JA, van der Goot FG. Systemic hyalinosis mutations in the CMG2 ectodomain leading to loss of function through retention in the endoplasmic reticulum. Human Mutation. 30: 583-9. PMID 19191226 DOI: 10.1002/Humu.20872 |
0.575 |
|
| 2009 |
Sangodkar J, Shi J, DiFeo A, Schwartz R, Bromberg R, Choudhri A, McClinch K, Hatami R, Scheer E, Kremer-Tal S, Martignetti JA, Hui A, Leung WK, Friedman SL, Narla G. Functional role of the KLF6 tumour suppressor gene in gastric cancer. European Journal of Cancer (Oxford, England : 1990). 45: 666-76. PMID 19101139 DOI: 10.1016/J.Ejca.2008.11.009 |
0.646 |
|
| 2009 |
DiFeo A, Martignetti JA, Narla G. The role of KLF6 and its splice variants in cancer therapy. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 12: 1-7. PMID 19097929 DOI: 10.1016/J.Drup.2008.11.001 |
0.694 |
|
| 2009 |
Xiong SD, Yu K, Liu XH, Yin LH, Kirschenbaum A, Yao S, Narla G, DiFeo A, Wu JB, Yuan Y, Ho SM, Lam YW, Levine AC. Ribosome-inactivating proteins isolated from dietary bitter melon induce apoptosis and inhibit histone deacetylase-1 selectively in premalignant and malignant prostate cancer cells (International Journal of Cancer (2009) 125, (774-782)) International Journal of Cancer. 125: 1995. DOI: 10.1002/Ijc.24691 |
0.379 |
|
| 2008 |
Narla G, DiFeo A, Fernandez Y, Dhanasekaran S, Huang F, Sangodkar J, Hod E, Leake D, Friedman SL, Hall SJ, Chinnaiyan AM, Gerald WL, Rubin MA, Martignetti JA. KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. The Journal of Clinical Investigation. 118: 2711-21. PMID 18596922 DOI: 10.1172/Jci34780 |
0.656 |
|
| 2008 |
DiFeo A, Feld L, Rodriguez E, Wang C, Beer DG, Martignetti JA, Narla G. A functional role for KLF6-SV1 in lung adenocarcinoma prognosis and chemotherapy response. Cancer Research. 68: 965-70. PMID 18250346 DOI: 10.1158/0008-5472.Can-07-2604 |
0.641 |
|
| 2007 |
Teixeira MS, Camacho-Vanegas O, Fernandez Y, Narla G, DiFeo A, Lee B, Kalir T, Friedman SL, Schlecht NF, Genden EM, Urken M, Brandwein-Gensler M, Martignetti JA. KLF6 allelic loss is associated with tumor recurrence and markedly decreased survival in head and neck squamous cell carcinoma. International Journal of Cancer. 121: 1976-83. PMID 17621627 DOI: 10.1002/Ijc.22926 |
0.664 |
|
| 2007 |
Camacho-Vanegas O, Narla G, Teixeira MS, DiFeo A, Misra A, Singh G, Chan AM, Friedman SL, Feuerstein BG, Martignetti JA. Functional inactivation of the KLF6 tumor suppressor gene by loss of heterozygosity and increased alternative splicing in glioblastoma. International Journal of Cancer. Journal International Du Cancer. 121: 1390-5. PMID 17514651 DOI: 10.1002/Ijc.22809 |
0.664 |
|
| 2007 |
Mosig RA, Dowling O, DiFeo A, Ramirez MC, Parker IC, Abe E, Diouri J, Aqeel AA, Wylie JD, Oblander SA, Madri J, Bianco P, Apte SS, Zaidi M, Doty SB, et al. Loss of MMP-2 disrupts skeletal and craniofacial development and results in decreased bone mineralization, joint erosion and defects in osteoblast and osteoclast growth. Human Molecular Genetics. 16: 1113-23. PMID 17400654 DOI: 10.1093/Hmg/Ddm060 |
0.725 |
|
| 2007 |
Phadke SR, Ramirez M, Difeo A, Martignetti JA, Girisha KM. Torg-Winchester syndrome: lack of efficacy of pamidronate therapy. Clinical Dysmorphology. 16: 95-100. PMID 17351352 DOI: 10.1097/Mcd.0B013E3280147187 |
0.556 |
|
| 2007 |
Kremer-Tal S, Narla G, Chen Y, Hod E, DiFeo A, Yea S, Lee JS, Schwartz M, Thung SN, Fiel IM, Banck M, Zimran E, Thorgeirsson SS, Mazzaferro V, Bruix J, et al. Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. Journal of Hepatology. 46: 645-54. PMID 17196295 DOI: 10.1016/J.Jhep.2006.10.012 |
0.59 |
|
| 2007 |
Kupferman ME, Rhee JS, Teixeira MS, Camacho-Vanegas O, Fernandez Y, Narla G, Difeo A, Schlecht NF, Brandwein-Gensler M, Martignetti JA. 10:30: KLF6 LOH Is Linked to Recurrence and Lower Survival in HNSSC Otolaryngology–Head and Neck Surgery. 137: P77-P78. DOI: 10.1016/J.Otohns.2007.06.095 |
0.535 |
|
| 2006 |
Utsch B, DiFeo A, Kujat A, Karle S, Schuster V, Lenk H, Jacobs U, Müller M, Dötsch J, Rascher W, Reutter H, Martignetti JA, Ludwig M, Tröbs RB. Bladder exstrophy and Epstein type congenital macrothrombocytopenia: evidence for a common cause? American Journal of Medical Genetics. Part A. 140: 2251-3. PMID 16969870 DOI: 10.1002/Ajmg.A.31454 |
0.54 |
|
| 2006 |
DiFeo A, Narla G, Hirshfeld J, Camacho-Vanegas O, Narla J, Rose SL, Kalir T, Yao S, Levine A, Birrer MJ, Bonome T, Friedman SL, Buller RE, Martignetti JA. Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 3730-9. PMID 16778100 DOI: 10.1158/1078-0432.Ccr-06-0054 |
0.663 |
|
| 2006 |
DiFeo A, Narla G, Camacho-Vanegas O, Nishio H, Rose SL, Buller RE, Friedman SL, Walsh MJ, Martignetti JA. E-cadherin is a novel transcriptional target of the KLF6 tumor suppressor. Oncogene. 25: 6026-31. PMID 16702959 DOI: 10.1038/Sj.Onc.1209611 |
0.622 |
|
| 2005 |
Park JH, Eliyahu E, Narla G, DiFeo A, Martignetti JA, Schuchman EH. KLF6 is one transcription factor involved in regulating acid ceramidase gene expression Biochimica Et Biophysica Acta - Gene Structure and Expression. 1732: 82-87. PMID 16500425 DOI: 10.1016/J.Bbaexp.2006.01.002 |
0.615 |
|
| 2005 |
Narla G, DiFeo A, Yao S, Banno A, Hod E, Reeves HL, Qiao RF, Camacho-Vanegas O, Levine A, Kirschenbaum A, Chan AM, Friedman SL, Martignetti JA. Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. Cancer Research. 65: 5761-8. PMID 15994951 DOI: 10.1158/0008-5472.Can-05-0217 |
0.665 |
|
| 2005 |
Narla G, Difeo A, Reeves HL, Schaid DJ, Hirshfeld J, Hod E, Katz A, Isaacs WB, Hebbring S, Komiya A, McDonnell SK, Wiley KE, Jacobsen SJ, Isaacs SD, Walsh PC, et al. A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Research. 65: 1213-22. PMID 15735005 DOI: 10.1158/0008-5472.Can-04-4249 |
0.651 |
|
| 2004 |
Kremer-Tal S, Reeves HL, Narla G, Thung SN, Schwartz M, Difeo A, Katz A, Bruix J, Bioulac-Sage P, Martignetti JA, Friedman SL. Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology (Baltimore, Md.). 40: 1047-52. PMID 15486921 DOI: 10.1002/Hep.20460 |
0.619 |
|
| 2003 |
Dowling O, Difeo A, Ramirez MC, Tukel T, Narla G, Bonafe L, Kayserili H, Yuksel-Apak M, Paller AS, Norton K, Teebi AS, Grum-Tokars V, Martin GS, Davis GE, Glucksman MJ, et al. Mutations in capillary morphogenesis gene-2 result in the allelic disorders juvenile hyaline fibromatosis and infantile systemic hyalinosis. American Journal of Human Genetics. 73: 957-66. PMID 12973667 DOI: 10.1086/378781 |
0.611 |
|
| 2003 |
Hirshfeld J, Narla G, Difeo A, Kalir T, Buller R, Friedman S, Martignetti J. KLF6 POLYMORPHISM IN PROSTATE CANCER REVEALS A NOVEL MECHANISM OF TUMOR SUPPRESSOR GENE INACTIVATION. Journal of Investigative Medicine. 51: 336.2-337. DOI: 10.1136/Jim-51-06-21 |
0.637 |
|
| Show low-probability matches. |